Literature DB >> 6408882

Secondary and essential cryoglobulinemias. Frequency, nosological classification, and long-term follow-up.

F Invernizzi, M Galli, G Serino, G Monti, P L Meroni, C Granatieri, C Zanussi.   

Abstract

The clinical and immunochemical classification of 166 patients with cryoglobulinemia are presented. 52% of the cryoglobulins were detected in patients hospitalized because of various causes. The most frequent association was with liver and lymphoproliferative diseases (in particular with Waldenström's macroglobulinemia); two thirds of the patients with liver diseases presented with a purpura-arthralgia syndrome, and the hepatic involvement was only brought to evidence by subsequent laboratory investigation. The presence of cryoglobulins did not usually interfere with the clinical course of the basic condition. In 79 patients the cryoglobulinemia was considered idiopathic. In order to study the natural course of the disease in the idiopathic cases, a group of 35 patients had been followed up for 8-17 years: 37% developed a membranous proliferative glomerulonephritis, and more than half died of renal insufficiency; in 11% cirrhosis was diagnosed after a period of 4-9 years; another 11% developed a lymphoproliferative disease; of the remaining 40%, 2 are still asymptomatic, and the others are affected by purpura-arthralgia syndrome.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6408882     DOI: 10.1159/000206699

Source DB:  PubMed          Journal:  Acta Haematol        ISSN: 0001-5792            Impact factor:   2.195


  15 in total

Review 1.  Therapeutic approaches in mixed cryoglobulinemia.

Authors:  D Geltner
Journal:  Springer Semin Immunopathol       Date:  1988

Review 2.  The kidney in mixed cryoglobulinemias.

Authors:  D J Cordonnier; J C Renversez; P Vialtel; E Dechelette
Journal:  Springer Semin Immunopathol       Date:  1987

3.  Acute renal failure secondary to severe type I cryoglobulinemia following rituximab therapy for Waldenström's macroglobulinemia.

Authors:  Aisha Shaikh; Thomas M Habermann; Mary E Fidler; Shaji Kumar; Nelson Leung
Journal:  Clin Exp Nephrol       Date:  2008-02-22       Impact factor: 2.801

4.  Spontaneous and pokeweed mitogen induced production of rheumatoid factor and immunoglobulins in type II essential mixed cryoglobulinaemia.

Authors:  R A Sinico; G Fiorini; A Fornasieri; P Bernasconi; S Benuzzi; M L Paracchini; G D'Amico
Journal:  Ann Rheum Dis       Date:  1986-07       Impact factor: 19.103

Review 5.  Hepatitis C virus and non-Hodgkin's lymphomas: Meta-analysis of epidemiology data and therapy options.

Authors:  Gabriele Pozzato; Cesare Mazzaro; Luigino Dal Maso; Endri Mauro; Francesca Zorat; Giulia Moratelli; Pietro Bulian; Diego Serraino; Valter Gattei
Journal:  World J Hepatol       Date:  2016-01-18

6.  In vitro synthesis of IgM rheumatoid factor by lymphocytes from patients with essential mixed cryoglobulinemia.

Authors:  P L Meroni; W Barcellini; R A Sinico; A Fornasieri; C Sguotti; F Invernizzi; G D'Amico; C Zanussi
Journal:  Clin Exp Immunol       Date:  1986-08       Impact factor: 4.330

Review 7.  Hepatitis C virus infection induced vasculitis.

Authors:  Patrice Cacoub; David Saadoun
Journal:  Clin Rev Allergy Immunol       Date:  2008-10       Impact factor: 8.667

8.  Hepatitis C virus (HCV)-related cryoglobulinemia: cryoglobulin type and anti-HCV profile.

Authors:  Martha Minopetrou; Emilia Hadziyannis; Melanie Deutsch; Maria Tampaki; Asimina Georgiadou; Eleni Dimopoulou; Dimitrios Vassilopoulos; John Koskinas
Journal:  Clin Vaccine Immunol       Date:  2013-03-06

Review 9.  Extrahepatic manifestations and autoantibodies in patients with hepatitis C virus infection.

Authors:  Takashi Himoto; Tsutomu Masaki
Journal:  Clin Dev Immunol       Date:  2012-09-05

Review 10.  Molecular signatures of hepatitis C virus (HCV)-induced type II mixed cryoglobulinemia (MCII).

Authors:  Giuseppe Sautto; Nicasio Mancini; Massimo Clementi; Roberto Burioni
Journal:  Viruses       Date:  2012-11-08       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.